ArticleCancer prevention research (Philadelphia, Pa.)2018
Longer-term Lipid-lowering Drug Use and Risk of Incident and Fatal Prostate Cancer in Black and White Men in the ARIC Study.
Article in Cancer prevention research (Philadelphia, Pa.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Tumor Cholesterol Synthesis, Statin Use, and Lethal Prostate Cancer.Molecular cancer research : MCR · 2025Article
- Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention.Journal of the National Cancer Institute · 2025Article
- Longitudinal cohort study highlights cancer-preventive benefits of lipid-lowering drugs.iScience · 2024Article
- Prostate Cancer and the Mevalonate Pathway.International journal of molecular sciences · 2024Review
- Liver Fibrosis Scores and Prostate Cancer Risk and Mortality in the Atherosclerosis Risk in Communities Study.Cancer prevention research (Philadelphia, Pa.) · 2023Article
- Rhabdomyolysis-induced acute kidney injury after administration of a red yeast rice supplement: A case report.World journal of clinical cases · 2023Article
- Total-, LDL-, and HDL-cholesterol, apolipoproteins, and triglycerides with risk of total and fatal prostate cancer in Black and White men in the ARIC study.The Prostate · 2023Article
- Article
- The Association of Prediagnostic Statin Use with Aggressive Prostate Cancer from the Multiethnic Cohort Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Association of Statin Use with the Risk of Incident Prostate Cancer: A Meta-Analysis and Systematic Review.Journal of oncology · 2022Article
- Lipid-Lowering Drug Use and Cancer Incidence and Mortality in the ARIC Study.JNCI cancer spectrum · 2021Article
- Pooled Cohort Equations and the competing risk of cardiovascular disease versus cancer: Multi-Ethnic study of atherosclerosis.American journal of preventive cardiology · 2021Article
- Independent and Joint Effects of Testosterone Replacement Therapy and Statins use on the Risk of Prostate Cancer Among White, Black, and Hispanic Men.Cancer prevention research (Philadelphia, Pa.) · 2021Article
- Differences in the prevalence of modifiable risk and protective factors for prostate cancer by race and ethnicity in the National Health and Nutrition Examination Survey.Cancer causes & control : CCC · 2020Article
- Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- Aspirin and Non-Aspirin NSAID Use and Prostate Cancer Incidence, Mortality, and Case Fatality in the Atherosclerosis Risk in Communities Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Lipid-lowering medications, particularly statins, may protect against aggressive prostate cancer. Fatal prostate cancer, the most clinically relevant outcome, remains understudied for this association. We prospectively studied lipid-lowering medication use and both incident and fatal prostate cancer in black and white men in the Atherosclerosis Risk in Communities (ARIC) study. A total of 6,518 men without cancer at visit 2 (1990-1992), the start of the statin era, were followed for prostate cancer incidence and death through 2012. Medication use was collected during study visits and telephone calls at up to nine time points during follow-up. Cox regression was used to estimate HR and 95% confidence intervals (CI) of total (white
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.